ASX & Press Releases

Thursday, June 5, 2014

Alchemia announced today that they expect to report the top-line results from the pivotal Phase III trial of HA-Irinotecan in metastatic colorectal cancer (mCRC) before the end of 3Q CY 2014 with FDA/EMA submissions expected in 1H 2015.

Monday, June 2, 2014

Alchemia today reports profit share of A$2.36 million (US$2.18 million) for the quarter ended 31 March 2014, on sales of its generic anti-coagulant drug fondaparinux. Alchemia will receive A$1.82 million (US$1.68 million) following its contribution of A$0.54 million (US$0.50 million) towards yield and cost of goods improvement activities, as previously announced.

Tuesday, April 8, 2014

Alchemia Limited today announced that it will be presenting propriety data at the American Association for Cancer Research (AACR) Annual Meeting 2014. The poster presentation entitled "The characterisation of hyaluronan-related enzymes in breast cancer cell subpopulations". See the poster presentation by clicking here.

Wednesday, March 5, 2014

Alchemia announced the in-licensing of two early-stage anticancer drug candidates from Cancer Research Technology (CRT). The preclinical Focal Adhesion Kinase (FAK) inhibitors originate from the Australian Cancer Therapeutics CRC (CTx) and will be evaluated by Alchemia in various cancer and cancer stem cell models prior to initiation of formal preclinical and clinical development.

Monday, March 3, 2014

Thomas Liquard, the Company’s Chief Executive Officer, will present a corporate overview at the 26th Annual ROTH Conference. Mr Liquard’s presentation will take place on Wednesday, March 12th, 2014 at 10:00AM PST at The Ritz Carlton in Dana Point, California.

Monday, March 3, 2014

Here we provide the slides that Thomas Liquard, CEO, will present at the 34th Annual Cowen & Co. Health Care Conference held in Boston, MA.

Watch the Webcast at http://wsw.com/webcast/cowen16/acl.ax

Thursday, February 27, 2014

Thomas Liquard, the Company’s Chief Executive Officer will present a corporate overview at the 34th Annual Cowen Health Care Conference. Mr. Liquard’s presentation will take place on Monday, March 3rd, 2014 at 4:50PM EST at the Boston Marriott Copley Place in Boston, Massachusetts

Monday, February 24, 2014

The Company is pleased to announce the appointment of Thomas Liquard as Chief Executive Officer. Mr Liquard brings significant commercial and managerial expertise to the company having most recently served as Senior Director, Portfolio Development Lead Emerging Markets for the Established Products portfolio at Pfizer, Inc. in New York.

Monday, February 17, 2014

The Company has provided a short investor update presentation on the quarterly sales and profit share for fondaparinux from Dr Reddy's Laboratory.

Monday, February 17, 2014

The company, today reports profit share of A$2.8 million (US$2.5 million) for the quarter ended 31 December 2013, on sales of its generic anti-coagulant drug fondaparinux.

Pages